{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:24:47Z","timestamp":1791267887806,"version":"4.1.0"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/inf.0000000000000224","type":"journal-article","created":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T08:16:55Z","timestamp":1388564215000},"page":"734-740","source":"Crossref","is-referenced-by-count":41,"title":["Metabolic Complications of in utero Maternal HIV and Antiretroviral Exposure in HIV-exposed Infants"],"prefix":"10.1097","volume":"33","author":[{"given":"Jennifer","family":"Jao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","volume":"331","author":"Connor","year":"1994","journal-title":"N Engl J Med"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/COH.0b013e3282f50bfe","article-title":"Antiretroviral treatment in pregnancy.","volume":"3","author":"Stek","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"key":"R3-14-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14740338.4.2.323","article-title":"The safety of antiretroviral drugs in pregnancy.","volume":"4","author":"Thorne","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajog.2004.05.061","article-title":"Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.","volume":"191","author":"Watts","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/338371a0","article-title":"Rise and fall of Western diseases.","volume":"338","author":"Barker","year":"1989","journal-title":"Nature"},{"key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)90710-1","article-title":"Weight in infancy and death from ischaemic heart disease.","volume":"2","author":"Barker","year":"1989","journal-title":"Lancet"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0143-4004(88)90007-0","article-title":"Morphological aspects of the placenta in HIV pregnancies.","volume":"9","author":"Jauniaux","year":"1988","journal-title":"Placenta"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijgo.2012.06.016","article-title":"Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression.","volume":"119","author":"Vermaak","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/317634","article-title":"Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand.","volume":"182","author":"Schwartz","year":"2000","journal-title":"J Infect Dis"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1471-0528.2008.01672.x","article-title":"Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study.","volume":"115","author":"Habib","year":"2008","journal-title":"BJOG"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/humrep\/des090","article-title":"Maternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa.","volume":"27","author":"Ndirangu","year":"2012","journal-title":"Hum Reprod"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ije\/24.5.1022","article-title":"The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi.","volume":"24","author":"Taha","year":"1995","journal-title":"Int J Epidemiol"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1258\/ijsa.2008.008446","article-title":"Anthropometric indices of infants born to HIV-1-infected mothers: a prospective cohort study in Lagos, Nigeria.","volume":"20","author":"Ezeaka","year":"2009","journal-title":"Int J STD AIDS"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002030-199103000-00008","article-title":"Perinatal transmission of HIV-1: lack of impact of maternal HIV infection on characteristics of livebirths and on neonatal mortality in Kigali, Rwanda.","volume":"5","author":"Lepage","year":"1991","journal-title":"AIDS"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/00002030-199814000-00012","article-title":"Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study.","volume":"12","author":"Sperling","year":"1998","journal-title":"AIDS"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(98)11046-2","article-title":"6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote dIvoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant.","volume":"353","author":"Dabis","year":"1999","journal-title":"Lancet"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1542\/peds.107.1.e5","article-title":"Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group.","volume":"107","author":"Chotpitayasunondh","year":"2001","journal-title":"Pediatrics"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.inf.0000207398.10466.0d","article-title":"Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.","volume":"25","author":"Briand","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-14-20210202","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1128\/AAC.48.4.1300-1306.2004","article-title":"Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2,3-dideoxy-5-fluoro-3-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.","volume":"48","author":"Feng","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0b013e328352d135","article-title":"Pediatric HIVAIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.","volume":"26","author":"Siberry","year":"2012","journal-title":"AIDS"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0b013e3182a7adb2","article-title":"P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.","volume":"64","author":"Ransom","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-14-20210202","doi-asserted-by":"crossref","first-page":"e1001217","DOI":"10.1371\/journal.pmed.1001217","article-title":"DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.","volume":"9","author":"Gibb","year":"2012","journal-title":"PLoS Med"},{"key":"R28-14-20210202","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa991159","article-title":"Antiretroviral therapy during pregnancy and the risk of an adverse outcome.","volume":"346","author":"Tuomala","year":"2002","journal-title":"N Engl J Med"},{"key":"R30-14-20210202","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/infdis\/jis553","article-title":"Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.","volume":"206","author":"Chen","year":"2012","journal-title":"J Infect Dis"},{"key":"R31-14-20210202","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/QAD.0b013e32830b8ab9","article-title":"Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote dIvoire.","volume":"22","author":"Ekouevi","year":"2008","journal-title":"AIDS"},{"key":"R32-14-20210202","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/infdis\/jis728","article-title":"Pediatric HIVAIDS Cohort Study. Combination antiretroviral use and preterm birth.","volume":"207","author":"Watts","year":"2013","journal-title":"J Infect Dis"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"e1525","DOI":"10.1542\/peds.2011-2340","article-title":"ACTG 5190PACTG 1054 Study Team. Infant outcomes after maternal antiretroviral exposure in resource-limited settings.","volume":"129","author":"Nielsen-Saines","year":"2012","journal-title":"Pediatrics"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"135030","DOI":"10.1155\/2012\/135030","article-title":"Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.","volume":"2012","author":"Aaron","year":"2012","journal-title":"Infect Dis Obstet Gynecol"},{"key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/adc.73.6.490","article-title":"Maternal HIV infection, drug use, and growth of uninfected children in their first 3 years.","volume":"73","author":"Ross","year":"1995","journal-title":"Arch Dis Child"},{"key":"R37-14-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.281.2.151","article-title":"Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219076 Teams.","volume":"281","author":"Culnane","year":"1999","journal-title":"JAMA"},{"key":"R39-14-20210202","first-page":"299","article-title":"Growth of uninfected infants exposed to antiretrovirals born to HIV-infected woman.","volume":"71","author":"Ibieta","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"R41-14-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QAI.0b013e3181ffa4f5","article-title":"Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.","volume":"56","author":"Powis","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-14-20210202","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.abb.2010.07.029","article-title":"HIV and bone disease.","volume":"503","author":"Stone","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"R43-14-20210202","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200204150-00004","article-title":"Bone mineral content is lower in prepubertal HIV-infected children.","volume":"29","author":"Arpadi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R44-14-20210202","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00002030-200109280-00011","article-title":"Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.","volume":"15","author":"Mora","year":"2001","journal-title":"AIDS"},{"key":"R45-14-20210202","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/jc.2003-030767","article-title":"Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.","volume":"89","author":"Mora","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-14-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R47-14-20210202","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-007-0524-8","article-title":"Risk factors for decreased bone density and effects of HIV on bone in the elderly.","volume":"19","author":"Jones","year":"2008","journal-title":"Osteoporos Int"},{"key":"R48-14-20210202","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"R49-14-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","article-title":"Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.","volume":"152","author":"Purdy","year":"2008","journal-title":"J Pediatr"},{"key":"R50-14-20210202","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.qai.0000184860.62189.c8","article-title":"A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.","volume":"40","author":"Giacomet","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R51-14-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042560-199904010-00001","article-title":"Administration of 9-2--(phosphonomethoxy)propyladenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.","volume":"20","author":"Tarantal","year":"1999","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R52-14-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042560-200203010-00001","article-title":"Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).","volume":"29","author":"Tarantal","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R53-14-20210202","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bone.2011.10.030","article-title":"Exposure to antiretroviral agents during pregnancy does not alter bone status in infants.","volume":"50","author":"Mora","year":"2012","journal-title":"Bone"},{"key":"R54-14-20210202","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","article-title":"In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.","volume":"16","author":"Vigano","year":"2011","journal-title":"Antivir Ther"},{"key":"R56-14-20210202","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(99)07219-0","article-title":"Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.","volume":"354","author":"Blanche","year":"1999","journal-title":"Lancet"},{"key":"R57-14-20210202","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.33.12.2109","article-title":"Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma.","volume":"33","author":"Konig","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R58-14-20210202","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","article-title":"Mitochondrial myopathy caused by long-term zidovudine therapy.","volume":"322","author":"Dalakas","year":"1990","journal-title":"N Engl J Med"},{"key":"R59-14-20210202","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/01.RES.74.2.344","article-title":"Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine.","volume":"74","author":"Lewis","year":"1994","journal-title":"Circ Res"},{"key":"R60-14-20210202","doi-asserted-by":"crossref","first-page":"21459","DOI":"10.1016\/S0021-9258(19)36631-1","article-title":"Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA.","volume":"267","author":"Copeland","year":"1992","journal-title":"J Biol Chem"},{"key":"R61-14-20210202","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1073\/pnas.63.3.871","article-title":"The enzymatic termination of polydeoxynucleotides by 2,3-dideoxyadenosine triphosphate.","volume":"63","author":"Toji","year":"1969","journal-title":"Proc Natl Acad Sci USA"},{"key":"R62-14-20210202","doi-asserted-by":"crossref","first-page":"18929","DOI":"10.1074\/jbc.270.32.18929","article-title":"Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase.","volume":"270","author":"Eriksson","year":"1995","journal-title":"J Biol Chem"},{"key":"R63-14-20210202","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/088922200308864","article-title":"Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3-azido-3-deoxythymidine.","volume":"16","author":"Gerschenson","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R64-14-20210202","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00042560-200006010-00003","article-title":"Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria.","volume":"24","author":"Ewings","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R65-14-20210202","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1385\/CT:5:3:333","article-title":"Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors.","volume":"5","author":"Divi","year":"2005","journal-title":"Cardiovasc Toxicol"},{"key":"R66-14-20210202","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/infdis\/jit146","article-title":"Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age.","volume":"208","author":"Olivero","year":"2013","journal-title":"J Infect Dis"},{"key":"R67-14-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/em.20433","article-title":"Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.","volume":"50","author":"Torres","year":"2009","journal-title":"Environ Mol Mutagen"},{"key":"R68-14-20210202","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/infdis\/jit149","article-title":"Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination.","volume":"208","author":"Andre-Schmutz","year":"2013","journal-title":"J Infect Dis"},{"key":"R69-14-20210202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00126334-200306010-00010","article-title":"Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.","volume":"33","author":"Poirier","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R70-14-20210202","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00002030-200404300-00009","article-title":"Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir.","volume":"18","author":"Divi","year":"2004","journal-title":"AIDS"},{"key":"R71-14-20210202","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00126334-200304010-00004","article-title":"Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.","volume":"32","author":"Shiramizu","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R72-14-20210202","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1542\/peds.2008-2771","article-title":"Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.","volume":"124","author":"Aldrovandi","year":"2009","journal-title":"Pediatrics"},{"key":"R73-14-20210202","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/591253","article-title":"Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.","volume":"198","author":"Cote","year":"2008","journal-title":"J Infect Dis"},{"key":"R74-14-20210202","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1310\/hct0902-126","article-title":"AIDS Clinical Trials Group A5084. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.","volume":"9","author":"McComsey","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R76-14-20210202","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1468-1293.2011.00945.x","article-title":"Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress.","volume":"13","author":"Ross","year":"2012","journal-title":"HIV Med"},{"key":"R77-14-20210202","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/135965350601100505","article-title":"Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.","volume":"11","author":"Maagaard","year":"2006","journal-title":"Antivir Ther"},{"key":"R78-14-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/135965350901400309","article-title":"Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy.","volume":"14","author":"Gingelmaier","year":"2009","journal-title":"Antivir Ther"},{"key":"R79-14-20210202","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/INF.0b013e31827030a6","article-title":"Abnormal newborn screens and acylcarnitines in HIV-exposed and ARV-exposed infants.","volume":"32","author":"Kirmse","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R80-14-20210202","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"R81-14-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1179\/027249309X12547917868880","article-title":"Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy.","volume":"29","author":"Shah","year":"2009","journal-title":"Ann Trop Paediatr"},{"key":"R82-14-20210202","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1542\/peds.2004-0955","article-title":"Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.","volume":"114","author":"Noguera","year":"2004","journal-title":"Pediatrics"},{"key":"R83-14-20210202","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1542\/peds.2006-0371","article-title":"Agence Nationale de Recherches Sur le SIDA 12011202 Ditrame Plus Study Group. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast.","volume":"118","author":"Ekouevi","year":"2006","journal-title":"Pediatrics"},{"key":"R84-14-20210202","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/INF.0b013e318234c886","article-title":"Pediatric HIVAIDS Cohort Study. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.","volume":"30","author":"Crain","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R85-14-20210202","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/00002030-200308150-00006","article-title":"French Perinatal Cohort Study Group. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.","volume":"17","author":"Barret","year":"2003","journal-title":"AIDS"},{"key":"R87-14-20210202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2000.tb05492.x","article-title":"Perinatal Safety Review Working Group; State and Local Health Department HIVAIDS Surveillance Programs. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance.","volume":"918","author":"Lindegren","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R88-14-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0b013e3181b3adc2","article-title":"Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants.","volume":"53","author":"Brogly","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R89-14-20210202","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJM200009143431102","article-title":"Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group.","volume":"343","author":"Lipshultz","year":"2000","journal-title":"N Engl J Med"},{"key":"R90-14-20210202","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e3280d5a786","article-title":"In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.","volume":"21","author":"Brogly","year":"2007","journal-title":"AIDS"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T11:28:39Z","timestamp":1688902119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201407000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000224","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}